ArticleAmerican journal of translational research2025
Clinical efficacy of azithromycin-budesonide combination therapy in pediatric Mycoplasma pneumoniae pneumonia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune dysregulation inFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical outcomes of adjunctive budesonide (BUD) therapy combined with azithromycin (AZM) in pediatric patients diagnosed with
methodsThis retrospective cohort analysis examined 120 pediatric MPP cases. Participants were stratified into either a control group (n=55, standard AZM treatment) or an observation group (n=65, AZM in combination with BUD) based on their treatment regimen. Comprehensive assessments included treatment efficacy, safety profiles, resolution of clinical manifestations, serum immunoglobulins, serum inflammatory markers, quality of life, and parental satisfaction. Additionally, univariate and multivariate logistic regression analyses were employed to identify independent predictors for therapeutic response.
resultsThe observation group exhibited a significantly superior clinical response rate, improved quality of life, and higher parental satisfaction than the control group, with no significant difference in adverse event incidence. Accelerated symptom resolution was observed in the observation group. Furthermore, significant immunomodulatory and anti-inflammatory effects were noted in the observation group. Univariate and multivariate analyses identified four independent predictors for treatment outcomes: disease duration (Odds Ratio [OR]=3.555, 95% Confidence Interval [CI]: 1.123-11.254), pre-treatment IgG levels (OR=0.280, 95% CI: 0.098-0.794), pre-treatment IL-6 levels (OR=3.848, 95% CI: 1.280-11.572), and therapeutic approach (OR=3.517, 95% CI: 1.200-10.304).
conclusionThe combination of AZM with BUD demonstrated superior therapeutic outcomes in pediatric MPP management, including accelerated symptom resolution, enhanced immune function, reduced inflammation, and improved quality of life and parental satisfaction, without increasing adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.